Sanofi GCVRZ 深 沪
等待开盘
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 --
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sanofi Drops Dupixent Successor Candidate After Assessing Data
Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety data, ending plans for regulatory filings.
07-25 02:10
Sanofi's Subcutaneous Sarclisa Escena Receives FDA Approval To Treat Multiple Myeloma
The US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa (isatuximab-irfc) Escena in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across
07-10 20:55
Can ARS Pharma's New CEO Unlock Neffy's Potential?
ARS Pharma (SPRY) co-founder Richard Lowenthal steps down as CEO. President Donn Casale succeeds him amid a strategic shift.
07-10 01:37
Sino Biopharma Accelerates Global Growth With GSK, AstraZeneca Partnerships
Sino Biopharma expanded its GSK partnership in China and signed an AstraZeneca licensing deal worth up to $2.1 billion.
07-08 22:14
AI 制药开始交卷，当效率红利兑现后，价值会流向谁？
文｜智讯智库分析师 李伯睿 AI 制药已经开始走进药企巨头的日常工作流。 强生（NYSE: JNJ）率先交出一份颇有说服力的成绩单：先导化合物优化时间直接砍半...
07-01 15:04
EU Launches Antitrust Probe Into Sanofi Over Allegedly Misleading Flu Vaccine Claims (UPDATED)
EU opens antitrust probe into Sanofi over claims it disparaged rival flu vaccine Fluad in Germany and France.
06-29 23:44
Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study
HC Wainwright sees over $1 billion in sales potential for Argenx's Vyvgart in IMNM despite myositis trial changes.
06-26 01:57
Europe Approves Sanofi's Multiple Sclerosis Drug Despite FDA Rejection
Sanofi won European approval for Cenrifki in SPMS and secured Japan authorization for Wayrilz in chronic ITP.
06-24 00:21
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.
06-22 21:15
FDA OKs Sanofi Diabetes Drug In Newly Diagnosed Pediatric Patients
FDA grants accelerated approval to Sanofi Tzield for children with newly diagnosed stage 3 type 1 diabetes, backed by Phase 3 data.
06-16 01:15
